Cargando…
A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans. Despite several emerging vaccines, there remains no verifiable therapeutic targeted specifically to the virus. Here we present a highly effective small interfering RNA (...
Autores principales: | Idris, Adi, Davis, Alicia, Supramaniam, Aroon, Acharya, Dhruba, Kelly, Gabrielle, Tayyar, Yaman, West, Nic, Zhang, Ping, McMillan, Christopher L.D., Soemardy, Citradewi, Ray, Roslyn, O’Meally, Denis, Scott, Tristan A., McMillan, Nigel A.J., Morris, Kevin V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118699/ https://www.ncbi.nlm.nih.gov/pubmed/33992805 http://dx.doi.org/10.1016/j.ymthe.2021.05.004 |
Ejemplares similares
-
Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection
por: Supramaniam, Aroon, et al.
Publicado: (2023) -
Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2
por: Scott, Tristan A., et al.
Publicado: (2022) -
Development of novel lipidic particles for siRNA delivery that are highly effective after 12 months storage
por: Clarke, Daniel, et al.
Publicado: (2019) -
Development of an intravaginal ring for the topical delivery of Aurora kinase A inhibitor, MLN8237
por: Tayyar, Yaman, et al.
Publicado: (2019) -
Broadly active zinc finger protein-guided transcriptional activation of HIV-1
por: Scott, Tristan A., et al.
Publicado: (2020)